DISCLAIMER:This blog does not intend to provide diagnosis...
This blog does not intend to provide diagnosis, treatment, or medical advice. Read more. The content provided on this blog is for informational purposes only. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. Information on this blog should not be considered as a substitute for advice from a healthcare professional. The claims made about specific products throughout this blog are not approved to diagnose, treat, cure, or prevent disease.
Research on the intestinal microbiome is uncovering potential new probiotic species that could revolutionize medicine. The gut microbiome is a complex and diverse system composed of genetic material from trillions of microorganisms (microbiota). Without question, the microbiome is a huge contributor to our health and wellness.
Research shows that the microbiome profoundly impacts various systems and plays crucial roles in digestive, immune, and mental health. An imbalance in the intestinal microbiome may lead to a wide range of issues, ranging from occasional symptoms of digestive distress like gas and bloating to broader systemic challenges such as obesity, diabetes, Alzheimer's disease, inflammation, etc.
The bacteria Akkermansia muciniphila is particularly exciting as it plays a key role in the health of the gut lining as well as promote improved insulin action to help fight obesity and blood sugar control. The effects are not limited to its live probiotic effects but rather to some of the compounds that the bacteria itself manufactures.
As a result, A. muciniphila has been shown to be more effective when it is dead vs. live. It is not alone in this effect; several lactic acid-producing probiotic organisms, such as Lactobacillus and Bifidobacter species, have also been effective when heat-killed. The effectiveness of these "zombie" or dead microbes is challenging the commercial dogma that the only effective probiotic bacteria live as expressed in colony-forming units (CFUs). That is not the case for A. muciniphila.
Akkermansia muciniphila plays a critical role in the mucin layer's health, protecting the cells that line the intestinal tract. That is why it is given its strain name muciniphila – the Latin suffix phila means love. So, muciniphila translates as "love of mucin."
A. muciniphila works with the epithelial cells that line the intestines to produce mucin. And that goes a long way in protecting the gut lining from damage. Not surprisingly, higher levels of A. muciniphila are associated with improved intestinal barrier function, reduced intestinal permeability (leaky gut), and improved overall digestive and absorptive function. Without sufficient A. muciniphila, the gut barrier is compromised, leading to the absorption of gut-derived toxins that overstimulate the immune system and produce a lot of inflammation. These gut-derived toxins can also lead to a condition known as non-alcoholic fatty liver disease and produce systemic inflammatory effects that can lead to arthritis, skin disorders, cardiovascular disease, and brain disorders.1-6
All the effects on the mucin layer by Akkermansia muciniphila are exciting, but what makes researchers excited are its effects on diabetes and obesity.
As the levels of A. muciniphila go down in the human microbiome, obesity, diabetes, inflammation, and metabolic disorders increase. And as the levels of A. muciniphila go up in the human microbiome, the rates of obesity, diabetes, inflammation, and metabolic disorders decrease. The assumption is that these disorders are associated with altered gut barrier function due to reduced mucin protection, which leads to the absorption of many gut-derived toxins that trigger a cascade of different systems that promote chronic inflammation and insulin resistance.1-7
The first human clinical trial with Akkermansia muciniphila was published in the online edition of Nature Medicine on July 1, 2019. Thirty-two subjects with pre-diabetes and evidence of metabolic syndrome (abdominal obesity, elevated blood lipids, high blood pressure, etc.) were randomized to get either a placebo or live or heat-killed (pasteurized) A. muciniphila. The active treatment groups taking A. muciniphila took around 10 billion bacteria (either dead or alive) daily for three months.
The primary purpose of the study was to evaluate safety. A muciniphila passed that test with flying colors. It also displayed effects noted on multiple markers of metabolism and overall health. Compared with placebo, insulin sensitivity increased while total cholesterol and some markers of inflammation and liver function improved. There was also a significant decrease in the white blood cell (WBC) count in those who got the bacteria. The thought is that strengthening the gut barrier led to a reduced absorption of gut-derived toxins that trigger an increase in white blood cell levels. Absorption of gut-derived toxins is also a huge factor in causing impaired liver function.
Here is the exciting part of the study, the dead bacteria outperformed the live bacteria. I have been stressing this effect for certain probiotics for years, but mainly to deaf ears. The marketplace is focused on colony-forming units over clinical data. That is a mistake. The focus should be on clinically tested forms and dosages.
There is a growing body of research on dead, non-viable probiotics, including their effectiveness in diarrhea and gastrointestinal infections, immune system enhancement and regulation, modulation of gut microbiota, and recovery from intestinal injury.
These bacterial preparations are known as "ghost probiotics," "postbiotics," "inactivated probiotics," and now "para probiotics." The benefits of some products have nothing to do with the organism being alive but instead are due to unique cellular components of the bacteria that are there, whether the bacteria is alive or dead.8 That is the case with A. muciniphila.
One of the critical features of A. muciniphila is that it is very "slimy" because it is covered in molecules known as exopolysaccharides. These slimy compounds prevent white blood cells from breaking down a beneficial protein known as Amuc_1100, found in the cell membrane surrounding A. muciniphila. It turns out that this protein is the secret to the bacteria's beneficial effects.
When purified Amuc_1100 is given to mice it exerts the same effects as the live or heat-killed bacteria. The heat-killed bacteria produce better effects than the live form of A. muciniphila because it removes the exopolysaccharides coating but leaves the Amuc_1100 intact. Amuc_1100 then acts on cells that line the intestines to tighten up the space between the cells, reduce inflammation, and prevent the absorption of gut-derived toxins that lead to insulin resistance, non-alcoholic fatty liver disease, obesity, and type 2 diabetes.1-6
As a probiotic, live Akkermansia muciniphila may help improve the level of the bacteria in the gut microbiome. And this increase could result in clinical benefits. Another double-blind study in 76 subjects with type 2 diabetes featured a probiotic formula that contained live A. muciniphila with four other bacteria: Clostridium beijerinckii, Clostridium butyricum, Bifidobacterium infantis, and Anaerobutyricum hallii.9 Subjects in the probiotic group who were also taking the drug metformin this probiotic at a dosage of 3 capsules twice daily for 12 weeks experienced improvement in blood sugar control compared to the placebo group.
Specifically, after 12 weeks of supplementation compared to baseline measurement, modest improvements were noted in blood sugar measurements in a standard 3-hour meal-tolerance test and A1C levels. A1C is a measurement of 3-month blood sugar control. After 12 weeks of probiotic supplementation, the A1C measurement dropped by 0.6%. It needs to be discovered how much A. muciniphila contributed to the improvement as the other bacteria have some actions in supporting blood sugar control as well.
Though Akkermansia muciniphila is now available as a probiotic, it is also essential to take advantage of dietary factors that support the growth of this bacteria. The suitable organisms in our microbiome are often already there; they need nourishment like a lawn needs the suitable soil and fertilizer.
Focusing on creating suitable "soil" and "fertilizers" to grow A. muciniphila and other beneficial probiotics is important in establishing the optimum microbiome. A few things have been shown to be effective in promoting the growth of A. muciniphila, most notably a FODMAP diet, flavonoids, fish oils, and berberine.
FODMAP is an acronym for:
Not all FODMAPs are health-promoting. Here is a list of some common foods and ingredients that are high in health-promoting FODMAPs that can promote the growth of A. muciniphila:10
Flavonoids are plant pigments and health-promoting compounds found in berries, many other fruit, green tea, dark chocolate, green leafy vegetables, and legumes. They are critical to the health of the microbiome. Flavonoids have been shown to dramatically increase the growth of the A. muciniphila.10,11 Dietary sources of flavonoids also provide other components (e.g., prebiotic fibers) that promote a healthy microbiome. The flavonoid quercetin is a good choice for those looking for additional support, as are extracts of pomegranate, grapeseed, pine bark, green tea, or blueberry.
The omega-3 fatty acids in fish oils, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), exert profound effects on the microbiome, including an ability to support increased levels of A. muciniphila.13
Berberine is an alkaloid found in many plants, notably in goldenseal (Hydrastis canadensis) and barberry (Berberis vulgaris). Berberine exerts significant beneficial effects on digestive health and the microbiome, including increasing the levels of A. muciniphila. This effect partially explains its positive results seen in berberine supplementation in clinical trials in improving blood sugar, promoting weight management, supporting normal blood lipid levels, and improving liver function.14
One of the beneficial features of most healthy diets, like the Mediterranean diet, is that they are a rich source of compounds that promote the growth of A. muciniphila.
Popular diets like the ketogenic and paleo diets are often deficient in foods promoting this vital organism. It may be necessary for these individuals to supplement their diet with prebiotics, flavonoid-rich extracts, fish oils, and concentrated forms of plant foods like spirulina, barley grass juice, and other green products.
References:
By Dr. Michael Murray, N.D. 
